MelaFind® is intended for use on clinically atypical cutaneous pigmented lesions with one or more clinical or historical characteristics of melanoma, excluding those with a clinical diagnosis of melanoma or likely melanoma. MelaFind® is designed to be used when a dermatologist chooses to obtain additional information for a decision to biopsy. MelaFind® should NOT be used to confirm a clinical diagnosis of melanoma.
MelaFind® is only for use by physicians trained in the clinical diagnosis and management of skin cancer (i.e., dermatologists) who have also successfully completed a training program in the appropriate use of MelaFind®.
The MelaFind® result is one element of the overall clinical assessment of clinically atypical lesions. A “High Disorganization” MelaFind® output indicates lesions (which may include malignant melanoma, melanoma in situ, high grade dysplastic nevi and atypical melanocytic proliferation/hyperplasia) that should be considered for biopsy; the biopsy decision of a “Low Disorganization” MelaFind® output should be based on the remainder of the entire clinical context. Lesions that are “non-evaluable” by MelaFind® should be carefully re-evaluated for biopsy.
For more information on MelaFind, you can visit www.melafind.com.
Memberships & Affiliations
- American Academy of Dermatology
- American Medical Association
- American Society for Laser Medicine and Surgery
- American Society of Dermatologic Surgery